ImmunoGen Analysis
ImmunoGen is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of ImmunoGen delisted stock analysis is to determine its intrinsic value, which is an estimate of what ImmunoGen is worth, separate from its market price. There are two main types of ImmunoGen's stock analysis: fundamental analysis and technical analysis.
The ImmunoGen stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ImmunoGen is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. ImmunoGen Stock trading window is adjusted to America/New York timezone.
ImmunoGen |
ImmunoGen Stock Analysis Notes
About 91.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.28. ImmunoGen had not issued any dividends in recent years. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people. To learn more about ImmunoGen call Mark Enyedy at 781 895 0600 or check out https://www.immunogen.com.ImmunoGen Investment Alerts
| ImmunoGen is not yet fully synchronised with the market data | |
| ImmunoGen has some characteristics of a very speculative penny stock | |
| ImmunoGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M). | |
| ImmunoGen currently holds about 373.87 M in cash with (197.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.69. | |
| Over 91.0% of the company shares are owned by institutional investors |
ImmunoGen Upcoming and Recent Events
Earnings reports are used by ImmunoGen to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 26th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ImmunoGen Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.72 B.ImmunoGen Profitablity
The company has Profit Margin (PM) of (0.26) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23.ImmunoGen Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunoGen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunoGen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmunoGen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
White Lauren over a year ago Acquisition by White Lauren of 19519 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 27788 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 6792 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 166725 shares of ImmunoGen subject to Rule 16b-3 | ||
Richard Wallace over a year ago Exercise or conversion by Richard Wallace of 10000 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Exercise or conversion by Theresa Wingrove of 158641 shares of ImmunoGen subject to Rule 16b-3 | ||
White Lauren over a year ago Acquisition by White Lauren of 295975 shares of ImmunoGen subject to Rule 16b-3 | ||
Theresa Wingrove over a year ago Acquisition by Theresa Wingrove of 23400 shares of ImmunoGen subject to Rule 16b-3 |
ImmunoGen Outstanding Bonds
ImmunoGen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ImmunoGen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ImmunoGen bonds can be classified according to their maturity, which is the date when ImmunoGen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ImmunoGen to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |